Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Genex Pharmaceutical Inc (PK:GENX)

Business Focus: Advanced Medical Equipment & Technology

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
 
Company Contact
Address: 1801 Guangyin Building
Youyibeilu, Hexi District
TIANJIN TNJ 300074
Tel: N/A
Website: N/A
IR: N/A
Key People
Song Fuzhi
Chairman of the Board, President, Chief Executive Officer
Zhang Shuli
Chief Financial Officer, Treasurer
Sufen Ai
Secretary
Business Overview
Genex Pharmaceutical, Inc. (Genex) was considered a development-stage company prior to June 17, 2004. Genex was a start-up, Internet-based fulfillment company with offices in Vancouver, British Columbia, Canada. On June 8, 2004, Genex entered into a share purchase agreement with Tianjin Zhongjin Biology Development Co., Ltd. (Zhongjin). On June 17, 2004, the stock purchase made pursuant to the share purchase agreement was consummated and Zhongjin became a wholly owned subsidiary of Genex. Zhongjin engages in the business of producing and distributing Reconstituted Bone Xenograft (RBX), which is considered a medical device that accelerates bone healing. Zhongjin solely markets its medical devices to hospitals in China. Zhongjin distributes its medical devices to more than 500 hospitals in 30 provinces throughout China. Zhongjin also markets its medical devices to medical device customers in China that are not hospitals.
Financial Overview
For the fiscal year ended 31 December 2007, Genex Pharmaceutical Inc revenues increased 33% to $3.2M. Net income decreased 45% to $343K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was offset by Selling Expense increase of 53% to $1M (expense), Research & Development increase from $1K to $196K (expense).